Vertex Pharmaceuticals Incorporated Stock price
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
418 USD | +0.17% | +0.55% | +2.73% |
Mar. 21 | Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease | MT |
Mar. 21 | Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease | DJ |
Financials (USD)
Sales 2024 * | 10.73B | Sales 2025 * | 11.74B | Capitalization | 108B |
---|---|---|---|---|---|
Net income 2024 * | 3.9B | Net income 2025 * | 4.5B | EV / Sales 2024 * | 8.45 x |
Net cash position 2024 * | 17.11B | Net cash position 2025 * | 21.54B | EV / Sales 2025 * | 7.35 x |
P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
24.1
x | Employees | 5,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
Latest transcript on Vertex Pharmaceuticals Incorporated
1 day | +0.17% | ||
1 week | +1.43% | ||
Current month | -0.65% | ||
1 month | -3.00% | ||
3 months | +2.44% | ||
6 months | +19.55% | ||
Current year | +2.73% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.67% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 418 | +0.17% | 1,092,050 |
24-03-27 | 417.3 | -0.27% | 905,446 |
24-03-26 | 418.5 | +0.58% | 952,561 |
24-03-25 | 416 | +0.09% | 732,827 |
24-03-22 | 415.7 | -0.01% | 821,734 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B | |
-6.78% | 10.36B |